and ACHieve in non-anterior,
non-infectious uveitis (NIU)
The challenge of managing non-anterior NIU
Non-anterior NIU is a rare systemic disease,
the etiology of which is not yet fully understood. Consequently, the management of non-anterior NIU can be challenging and often requires immediate referral to a specialist non-anterior NIU center and ongoing interdisciplinary co-management.
To optimize outcomes, treatment should be initiated, monitored and potentially escalated according to the needs of individual patients.
Sharing expert knowledge
REACH is a global educational initiative aiming to improve quality of care of patients with non-anterior NIU.
REACH provides practical training tools and resources for ophthalmologists, rheumatologists and uveitis specialists who treat non-anterior NIU. The REACH program is informed and developed by leading international experts in the management of non-anterior NIU.
REACH Main Objectives and Mission
Accurate and timely referral of patients with suspected non-anterior NIU eligible for
Ensuring appropriate treatment escalation –
right patients, right time.
Ongoing collaboration between GO and specialists, event post-biologic treatment.
The REACH program is designed to raise awareness of the best clinical practices for patients with non-anterior NIU.
Our resources will help general ophthalmologists, uveitis specialists and rheumatologists to collaboratively optimize the management of their patients with non-anterior NIU.
Our aim is to create a platform of knowledge exchange and to facilitate implementation of best practices in patients with non-anterior NIU.
Improvement of patient outcomes is the ultimate goal of REACH.
About the REACH program
This video provides an overview of the REACH program and information about the REACH Tools and Resources
Miguel Cordero-Coma is Head of the Uveitis Unit, Department of Ophthalmology and an associate researcher at the Instituto de Biomedicina (IBIOMED), both at the University Hospital of León.
He received his medical degree from the University of Salamanca, Spain in 2001, and obtained his PhD in 2014. In 2005, Dr. Miguel Cordero-Coma received a fellowship in ocular immunology and uveitis at Harvard Medical School/Massachusetts Eye Research and Surgery Institute, and in 2006 he became Fellow of the European Board of Ophthalmology.
Dr Cordero-Coma has been the principal investigator for several clinical trials in uveitis and has authored or co-authored more than 80 articles and numerous book chapters with an emphasis on uveitis. Dr Cordero-Coma is a founding member, and current secretary, of the Spanish Society of Ocular Inflammation (SEIOC), an elected member of both the American Uveitis Society (AUS), and the International Uveitis Study Group (IUSG), and a member of the Foster Ocular Immunology Society (FOIS). Dr Cordero-Coma is section editor of the Journal of Ophthalmology and is a regular reviewer for several ophthalmological and immunological journals, as well as an advisor to the European Medicines Agency (EMA) on uveitis-related matters.
FRCOphth, FRCS Singapore
Dr Chee is a Senior Consultant and heads both the Cataract Subspecialty Service and Ocular Inflammation and Immunology Service at the Singapore National Eye Centre (SNEC). She is also Professor at National University of Singapore and Duke-National University of Singapore Graduate Medical School.
Dr Chee obtained her Masters at the National University of Singapore and became a Fellow of the Royal College of Surgeons, Glasgow, Edinburgh and College of Ophthalmologists, UK. In 1993, she completed her fellowship in uveitis, and also in oculoplastics, lacrimal and orbital surgery at Moorfield’s Eye Hospital, London.
Her research interests are in cytomegalovirus infection of the anterior segment, ocular tuberculosis, dengue maculopathy and Vogt-Koyanagi-Harada disease. She has special interest in developing new surgical techniques and instruments.
Dr Chee has published over 200 peer reviewed scientific papers and is a member of several editorial boards. She serves as the group lead member of the Cataract research team at the Singapore Eye Research Institute. Among others, she was conferred the Outstanding Clinician 2011 Award and the Singapore Health Quality Service Award 2014 (Gold) for her significant contributions. Recently in Oct 2017, she was admitted as a fellow of the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and in 2017, she was appointed treasurer of the Global Ocular Inflammation Workshop (GOIW).
MD, PhD Paris, France
Antoine Brézin is Professor of Ophthalmology at the Université Paris Descartes School of Medicine, Paris, France and Chair of the Department of Ophthalmology at the Cochin Hospital, Paris, France.
Prof Brézin received his medical degree from the Paris University Residency Program and obtained his PhD on the basis of his research in the field of inflammatory and genetic eye diseases. Internationally recognized in the field of intraocular inflammatory diseases, Prof Brézin’s research interests focus on uveitis. He is a member of the International Uveitis Study Group and he has participated actively in the work of the Standardization of Uveitis Nomenclature project.
Prof Brézin has published articles in all leading ophthalmology journals and has edited a book on uveitis published by the French Society of Ophthalmology. He has been involved in the VISUAL trials from the design of the studies to their completion.
MD Portland, USA
Dr James Rosenbaum is the only practising rheumatologist in the world to chair a department of ophthalmology. He is Professor of Ophthalmology, Medicine, and Cell Biology, Edward E Rosenbaum Professor of Inflammation Research, Chair of the Division of Arthritis and Rheumatic Diseases and Founder of The Uveitis Clinic at Oregon Health & Science University. Dr Rosenbaum is also the Richard Chenoweth Chair of Ophthalmology at Legacy Devers Eye Institute, Portland, Oregon, USA.
Dr Rosenbaum is the author of more than 575 original reports or book chapters, most of which are related to ocular inflammatory diseases. His work has been cited more than 23,000 times. His honours include the Friedenwald Award from ARVO, the Alcon Research Institute Scholar Award, the International Uveitis Study Group Foundation Gold Medal and the Clinician Scholar Award from the American College of Rheumatology. He is currently studying the role of the microbiome in the pathogenesis of uveitis and the use of gene expression profiling to understand orbital inflammatory diseases.
Athimalaipet V. Ramanan
FRCP, FRCPCH Bath, UK
Athimalaipet V. Ramanan is a consultant pediatric rheumatologist at the Bristol Royal Hospital for Children and the Royal National Hospital for Rheumatic Diseases, Bath, UK. He is the joint lead for research at the Bristol Royal Hospital for Children, and Professor of Paediatric Rheumatology at the University of Bristol.
Professor Ramanan’s research interests focus on biologics for uveitis in children with juvenile idiopathic arthritis (JIA), juvenile dermatomyositis, genetic aspects of JIA, and macrophage activation syndrome, and has published >120 articles and numerous book chapters covering a variety of topics in the field of rheumatology. He is Associate Editor for the Archives of Diseases in Childhood, and he is a member of the editorial board of Rheumatology.
Professor Ramanan is a medical advisor for the National Rheumatoid Arthritis Society and the National Ankylosing Spondylitis Society. He is also Chair for the National Institute for Health Research Clinical Research Network: Children/Arthritis Research UK (ARUK) Paediatric Rheumatology Clinical Studies Group, and Associate Director for the UK Experimental Arthritis Treatment Centre for Children (JIA-Uveitis and Industry work streams). He was awarded the British Society of Rheumatology’s Innovation in Clinical Practice Award in 2010. He is a scientific committee member of the ARUK/Medicines for Children Research Network (MCRN) Clinical Studies Group for Paediatric Rheumatology.
MBChB, MRCP, MRCOphth, PhD Oxford, UK
Dr Sharma is a Consultant Medical Ophthalmologist at Oxford Eye Hospital, Oxford and Honorary Lecturer at The University of Oxford. She leads the Regional Ocular Inflammatory Disease Service at Oxford University Hospitals NHS Trust. She is Chair of the UK National Uveitis Clinical Study Group.
Andrew D Dick
FMedSci, FRCOphth London, UK
Andrew Dick is a Director of UCL Institute of Ophthalmology, Duke Elder Professor of Ophthalmology, UCL Institute of Ophthalmology. He is also Professor of Ophthalmology at the University of Bristol and Faculty and Theme Lead for Inflammation and Immunotherapeutics of Moorfields Biomedical Research Centre, London.
Professor Dick was Director of Research for the Faculty of Medicine and Dentistry at University of Bristol. He has previously been Editor of British Journal of Ophthalmology, President of European Vision and Eye Research (EVER), Master of Oxford Ophthalmological Congress and current Vice-President for Association for Research in Vision and Ophthalmology (ARVO). Professor Dick leads the regional Ocular Inflammatory Service in the South West of England, UK. His work integrated into his clinical service spans through to early and late phase clinical trials in uveitis.
Professor Dick is a Fellow of the Academy of Medical Sciences in the UK for his significant contribution to research and scholarship and in 2011 was awarded the Alcon Research Institute award for outstanding research contribution. He was a steering committee member for global Standardised Uveitis Nomenclature working group, editorial board member of 5 international peer-reviewed journals, including most recently Progress in Retinal and Eye Research.
Role of the sponsor
The programme is sponsored by AbbVie Inc. as an educational initiative led by an independent Steering Committee of experts who develop all educational and scientific content which does not necessarily represent the views of AbbVie